The ophthalmic drug market has huge potential.
According to data, the size of China's ophthalmic drug market in 2021 will approach 26 billion yuan
.
With the aging of the population, changes in lifestyles, increased life pressure, and the popularization of electronic products, the scale of patients with eye diseases will continue to expand.
The annual market size will exceed 100 billion yuan
.
In the face of such a huge and sizable market, many domestic and foreign pharmaceutical companies are increasing their layout, and news of progress continues to come
.
Recently, CDE public information shows that Shijiazhuang Green Pharmaceutical's Tobramycin Eye Drops, Xianshi Pharmaceutical & Zhejiang Thermo Pharmaceutical's Sodium Hyaluronate Eye Drops, and Zhongshan Wanhan Pharmaceutical's Bromfenac Sodium Eye Drops, etc.
The ophthalmic drug application was accepted
.
Among them, tobramycin eye drops have not yet been reviewed by companies, and Shijiazhuang Green Pharmaceutical is expected to win the first review
.
The data shows that in 2021, the market growth rate of tobramycin eye drops has exceeded 10% in physical pharmacy terminals in Chinese cities
.
Bromfenac sodium eye drops was developed by Japan's Qianshou Pharmaceutical and was approved by the US FDA in March 2005
.
At present, in addition to Japan's Qianshou, domestic companies including Jinyao Pharmaceutical, Liaoning Meizilin Pharmaceutical, Qilu Pharmaceutical, Chenxin Fodu Pharmaceutical, Heyi Pharmaceutical and other companies have the approval number for bromfenac sodium eye drops
.
Among them, Jinyao Pharmaceutical Co.
, Ltd.
is the first company that has passed the evaluation of this variety
.
In recent years, domestic sales of bromfenac sodium eye drops have grown steadily, and in-hospital sales in the first half of 2021 have increased by 184% year-on-year
.
It is worth mentioning that bromfenac sodium eye drops have satisfied the centralized procurement, and the industry believes that it is expected to be included in the national centralized procurement in the future
.
Sodium hyaluronate eye drops are also commonly used in the treatment of dry eye
.
According to data from Minet.
com, the sales growth rate of sodium hyaluronate eye drops has exceeded 20% in recent years, and will exceed 300 million yuan in 2021
.
From the perspective of the market structure, USAPHARM has a relatively large market share, followed by Santen Pharmaceutical and United Laboratories
.
At present, in addition to Xianshi Pharmaceutical & Zhejiang Thermopharmaceuticals, 10 companies including Nanjing Hengdao Pharmaceuticals & Jiangsu Dahongying Hengshun Pharmaceuticals and Beijing Huienlande Pharmaceuticals are under review
.
According to industry statistics, since 2022, 5 ophthalmic drugs (15 product specifications) have been approved in China, among which diquafosol sodium eye drops from Chengdu Shengdi Pharmaceutical, a subsidiary of Hengrui Medicine, and hydrochloric acid from Sichuan Heyi Pharmaceutical Lidocaine ophthalmic gel is the first imitation in China
.
According to public information, diquafosol sodium eye drops were developed by Inspire Pharmaceuticals in the United States.
In 1998, Japan's Santen Pharmaceuticals cooperated with Inspire to obtain the right to develop and sell the drug in Japan and other Asian countries.
The product was approved in China in 2017.
listed
.
In May 2022, Chengdu Shengdi Medicine, a subsidiary of Hengrui Medicine, was approved as the 4th generic type of diquafosol sodium eye drops, becoming the first company to be imitated
.
Sichuan Heyi Pharmaceutical obtained the first copy of lidocaine hydrochloride ophthalmic gel in March 2022, which is suitable for surface inspection of ophthalmic surgery and ophthalmic examinations
.
In addition, as of now, there are still 28 ophthalmic drugs (139 product specifications) under review, among which Qilu Pharmaceutical, Jiangxi Kelun Pharmaceutical, Zhaoke (Guangzhou) Ophthalmic Drug and other companies are expected to win the first copy
.
After a large number of pharmaceutical companies have promoted the progress of ophthalmic drugs, the ophthalmic drug market has made waves again.
Facing the market of tens of billions, the competition among enterprises will be more intense in the future!
